Cargando…
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is rapidly becoming the leading indication for liver transplant and is associated with increased cardiovascular and liver mortality, yet there are no licensed therapies. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are widely used fo...
Autores principales: | Marjot, Thomas, Green, Charlotte J, Charlton, Catriona A, Cornfield, Thomas, Hazlehurst, Jonathan, Moolla, Ahmad, White, Sarah, Francis, Jane, Neubauer, Stefan, Cobbold, Jeremy FL, Hodson, Leanne, Tomlinson, Jeremy W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273735/ https://www.ncbi.nlm.nih.gov/pubmed/32514450 http://dx.doi.org/10.1002/jgh3.12274 |
Ejemplares similares
-
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis
por: Green, Charlotte J, et al.
Publicado: (2022) -
Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding
por: Low, Wee Suan, et al.
Publicado: (2018) -
Non-alcoholic fatty liver disease and diabetes
por: Hazlehurst, Jonathan M., et al.
Publicado: (2016) -
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents
por: Hazlehurst, Jonathan M., et al.
Publicado: (2022) -
Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD
por: Marjot, Thomas, et al.
Publicado: (2023)